MétaCan
Menu
Back to cohort
Record W2791179498 · doi:10.1111/cea.13114

The effects of a <scp>CCR</scp>3 inhibitor, <scp>AXP</scp>1275, on allergen‐induced airway responses in adults with mild‐to‐moderate atopic asthma

2018· article· en· W2791179498 on OpenAlexaff
Gail M. Gauvreau, J. Mark FitzGerald, L.‐P. Boulet, R. M. Watson, L. Hui, H. Villineuve, Tara Scime, Abbey Schlatman, Caitlin Obminski, Jennifer Kum, Stefen A. Boehme, Tai Wei Ly, Kevin B. Bacon, Paul M. O’Byrne

Bibliographic record

VenueClinical & Experimental Allergy · 2018
Typearticle
Languageen
FieldMedicine
TopicAsthma and respiratory diseases
Canadian institutionsInstitut universitaire de cardiologie et de pneumologie de QuébecUniversity of British ColumbiaMcMaster University
Fundersnot available
KeywordsMedicineAsthmaAllergenImmunologySputumPlaceboAllergyExhaled nitric oxideRespiratory diseaseEosinophil cationic proteinEosinophilInternal medicineGastroenterologySpirometryLungPathologyTuberculosis

Abstract

fetched live from OpenAlex

Summary Background CCR 3 is the cognate receptor for major human eosinophil chemoattractants from the eotaxin family of proteins that are elevated in asthma and correlate with disease severity. Objective This proof‐of‐mechanism study examined the effect of AXP 1275, an oral, small‐molecule inhibitor of CCR 3, on airway responses to inhaled allergen challenge. Methods Twenty‐one subjects with mild atopic asthma and documented early and late asthmatic responses to an inhaled aeroallergen completed a randomized double‐blind cross‐over study to compare early and late allergen‐induced asthmatic responses, methacholine PC 20 , blood and sputum eosinophils and exhaled nitric oxide after 2 weeks of treatment with once‐daily doses of AXP 1275 (50 mg) or placebo. Results There was a significant increase in methacholine PC 20 after 12 days of AXP 1275 treatment compared to placebo (increase of 0.92 doubling doses versus 0.17 doubling doses, P = .01), but this protection was lost post‐allergen challenge. There was no effect of AXP 1275 on allergen‐induced late asthmatic responses, or eosinophils in blood and sputum. The early asthmatic response and exhaled nitric oxide levels were slightly lower with AXP 1275, but this did not reach statistical significance. The number of subjects who experienced treatment‐emergent adverse events while receiving AXP 1275 was comparable placebo. Conclusions &amp; Clinical Relevance AXP 1275 50 mg administered daily was safe and well tolerated, and there was no difference in the type, severity or frequency of treatment‐emergent adverse events in subjects while receiving AXP 1275 compared to placebo. AXP 1275 increased the methacholine PC 20 ; however, the low and variable exposure to APX 1275 over a short treatment period may have contributed to poor efficacy on other outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.165
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.331
Teacher spread0.310 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations31
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueClinical & Experimental AllergySame topicAsthma and respiratory diseasesFrench-language works237,207